AA
AST.WS

Apriem Advisors’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Apriem Advisors’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed – – 684
2017
Q1 		$0 Hold
2
– – ﹤0.01% 785
2016
Q4 		$0 Hold
2
– – ﹤0.01% 788
2016
Q3 		$0 Hold
2
– – ﹤0.01% 702
2016
Q2 		$0 Buy
+2
New +$1 ﹤0.01% 693

Other funds holding AST.WS

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Apriem Advisors's AST.WS Position: Q2 2017 in Review

Apriem Advisors sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q2 2017, closing a stake of 2 shares.

Apriem Advisors first reported a position in AST.WS in Q2 2016 and held it in 4 quarters. The position peaked at $0 in Q1 2017. 33 funds tracked by Wall St. Rank hold AST.WS as of Q2 2017.

  • Apriem Advisors reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q2 2017 after selling out during the quarter.
  • Apriem Advisors sold 2 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q2 2017.
  • Apriem Advisors first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 4 quarters.
  • Apriem Advisors's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $0 in Q1 2017.
  • 33 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q2 2017.

Based on Apriem Advisors's 13F filing for Q2 2017, filed 4 Aug 2017.